Skip to main content
OpenTrials
Completed

NCT Number: NCT03009318

MRS and 11C-methionine PET/CT in the Diagnosis of Glioma

MET PET and MRS are often performed as imaging tool for the differential diagnosis of gliomas. But both techniques have limitations causing misdiagnosis; thus, the investigators tried to combine these two imaging tools to study whether the combination of MET PET and MRS could raise the diagnosis ability of the radiological diagnosis of gliomas.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Glioma Neoplasms Neoplasms by Histologic Type Neoplasms, Germ Cell and Embryonal Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue Neoplasms, Neuroepithelial Neuroectodermal Tumors

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Huashan hospital, Fudan university

Shanghai, 200040, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with non-enhancing supratentorial lesions shown by contrast-enhanced MRI
  • No surgery, chemotherapy or radiotherapy history
  • All patients gave written informed consent.

Exclusion criteria

  • Patients with infratentorial Neoplasms
  • Patients with enhancing supratentorial lesions
  • Recurrent gliomas after surgery
  • Primary gliomas with history of radiotherapy or chemotherapy
  • History of malignant tumours at any body site
  • Inability to give informed consent

Treatment and study plan

tumors are confirmed by surgery and pathology

Other

Each patient undergoes both MRS and MET PET scan before surgery. The lesion will be considered as a glioma when either MRS or MET PET results indicated the diagnosis. Pathologic diagnosis will be performed to confirm the final diagnosis.

Primary outcomes

  1. Sensitivity of the combination of MRS and 11C-MET PET/CT

    Time frame: 5 years

Secondary outcomes

  1. The relationship between 11C-MET PET/CT results and molecular pathogeneses

    Time frame: 5 years

Sponsors and collaborators

Lead sponsor

Huashan Hospital

Other

Registry information

Official study title

Combination of 11C-MET PET and MRS in the Diagnosis of Glioma.

Important dates

Study start
2012
Primary completion
2016
Study completion
2017
First posted
Jan 4, 2017
Registry last updated
Apr 9, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.